Key Dates

Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of General Medical Sciences (NIGMS)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)

Purpose

The purpose of this Notice is to highlight interest in administrative supplement applications from eligible investigators, focused on efforts to prevent, prepare for, and respond to infectious disease outbreaks.

NIH Institute, Center, and Office (ICO) Specific Research Interests

National Institute of Allergy and Infectious Diseases (NIAID)

• Active G20 Grants awarded under RFA-AI-21-022- Limited Competition: Facility and Building System Upgrades Support for the Regional Biocontainment Laboratories (G20 Clinical Trial Not Allowed) may request for Biosafety Level 3 (BSL3) renovations and facilities upgrades or purchase of equipment for BSL3.
• RBL-Affiliated Research Projects: Applicants with active NIAID or NIH research grants that require a BSL3 Biocontainment Facility and whose research projects are affiliated with one of the RBL sites for purposes of performance, whether the investigator is based at the RBL or another institution.

Example topics of interest:

• • Research projects requiring use of the RBL and related to the development and testing of new antiviral compounds or other therapeutics, new vaccines, and point of care diagnostics tests;
  • Research projects requiring use of the RBL on other prophylactic methods to prevent infections; and
  • Training new researchers in biosafety level 3 practices.

The proposed supplemental activities must be allowed within the original scope of the parent award. Construction activities will not be supported.

Application budgets are generally limited up to the amount of the current award (direct costs plus applicable F&A costs, as appropriate) and must reflect the actual needs of the proposed project. All activity codes of currently funded NIAID grants are eligible.

National Institute of General Medical Sciences (NIGMS)

NIGMS eligibility for this supplement program is limited to current awardees of the Institutional Development Award (IDeA) Networks for Clinical and Translational Research (IDeA-CTR, U54) and the Centers of Biomedical Research Excellence (COBRE, P20, P30) IDeA programs. The work proposed in the application must use the RBL’s BSL3 facilities for infectious disease research. Additionally, the supplement request must be consistent with the terms and conditions of the parent IDeA award.

Office of Research Infrastructure Programs (ORIP)

ORIP eligibility for this supplement program is limited to current awardees of National Primate Research Centers (NPRC, P51) with an RBL BSL-3. ORIP is interested in projects to enhance the RBL BSL3 for use of NHP models through renovations and facilities upgrades, purchase of equipment for the BSL3, or training of new researchers in BSL 3 practices for nonhuman primate research. A request may not exceed $499,999 in total cost.

Eligibility

• To be eligible, the parent award must be active, and the research proposed in the supplement must be accomplished within the competitive segment.
• Active awards cannot be in no-cost extension (NCE) at the time of the due date. Awards in NCE are ineligible to apply.
• Grantee organizations may submit more than one application, provided that each application is distinct from other administrative supplements or other types of grant applications already funded or under consideration by the NIH.
• Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• Application Due Date(s) – May 31, 2022, by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include “NOT-AI-22-049” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Applicants are strongly encouraged to notify both the Scientific/Research Contact(s) listed below and the Program Official in eRA Commons for the parent grant that a request has been submitted in response to this NOSI to facilitate efficient processing of the request.
• The process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.

Letter(s) of Support

All Applications:

• A formal letter of support (and NIH biographical sketch for any Senior/Key Personnel) must be provided for all newly proposed collaborative, consultative, and/or contract arrangements.

RBL-Affiliated Research Projects:

• A letter of support from the RBL director should be included with the supplement request.
• Applicants must include a letter from appropriate institutional biosafety officials, countersigned by the authorized organizational representative/institutional official, indicating that the planned studies are deemed safe for research personnel and the research environment.

Research Strategy

• The Research Strategy section of the application is limited to 6 pages, not including the References Cited. As part of the application, include the abstract from the parent award. Summarize the scope of the parent and supplemental projects, and describe the supplement's specific aims, including research design and methods, and data analysis. Clearly state how the supplemental work relates to the relevant specific aim(s) and scope of the parent award.

Budget

• Funds requested must reflect actual needs of the proposed project in achieving new objectives that are within scope of the parent projects.
• For parent awards with large unobligated balances, an explanation and plans for drawdown of those funds must be provided.
• The project and budget periods are limited to one year and must be within the currently approved project period for the existing parent award.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)

Mark S. Williams, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3327
Email: [email protected]

Pauline Cupit, Ph.D.
National Institute of General Medicine Sciences (NIGMS)
Email: [email protected]

Matthew Arnegard Ph.D.
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-451-2074
Email: [email protected]

Financial/Grants Management Contact(s)

Michael Fato
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2968
Email: [email protected]